Company Profile

Adaptimmune Therapeutics plc (NASDAQ: ADAP)
3:34 PM EDT, 04/26/24
Last: $1.08 Change: +0.02 %Change: +2.07% Volume: 1,098,779
Detailed Quote
Open: $ 1.06   Volume: 1,098,779
High: $ 1.09   Yield(%) 0.00
Low: $ 1.03   P/E Ratio (ttm): n/a
Dividend ($): n/a   Market Cap ($): 240.80M
EPS ($) -0.52   Shares Out: 227.17M
M = Million B = Billion
Price Performance
% Price Change (last 4 weeks): -32.91
% Price Change (last 13 weeks): 43.83
% Price Change (last 26 weeks): 89.29
% Price Change (last 52 weeks): -22.06
% Price Change (year to date): 33.67
Management Effectiveness
Return on Equity (%): -188.34
Return on Assets (%): -37.39
Return on Invested Capital (%): -83.26
Profitability
Gross Profit Margin (%): 83.71
Net Profit Margin (%): -188.90
Operating Profit Margin (%): -227.66
Price & Volume
50-day Moving Average: $1.38
200-day Moving Average: $0.90
Avg. Daily Vol. (last 50 days): 1,613,413
Avg. Daily Vol. (last 200 days): 1,016,349
52-wk high: $2.05
52-wk low: $0.42
Bid: $1.08
Ask: $1.09
Company Information
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
Adaptimmune Therapeutics plc
60 Jubilee Avenue Milton Park
Abingdon OX OX14 4RX

Phone: 44.1235.430000
Fax: n/a
http://www.adaptimmune.com
Per Share Data
Earnings (1year) ($): -0.52
Annual Dividend ($): 0.00
Current P/E Ratio (ttm): n/a
Book Value ($): 0.17
Cash Flow ($): -0.46
Valuation Ratios
Price/Earnings (x): n/a
Price/Sales (x): 2.63
Price/Book (x): 4.56
Price/Cash Flow (x): n/a
Financial Strength
Quick Ratio (x): 2.85
Current Ratio (x): 2.85
LT Debt/Equity (x): 50.24
Total Debt/Equity (x): 63.87



Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2021 Wall Street Horizon, Inc.